Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19 : The Potential of Autotaxin as a Therapeutic Target
Copyright © 2021 Ntatsoulis, Karampitsakos, Tsitoura, Stylianaki, Matralis, Tzouvelekis, Antoniou and Aidinis..
Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 12(2021) vom: 01., Seite 687397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ntatsoulis, Konstantinos [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.11.2021 Date Revised 07.11.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2021.687397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33211550X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33211550X | ||
| 003 | DE-627 | ||
| 005 | 20231226203732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.687397 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM33211550X | ||
| 035 | |a (NLM)34671341 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ntatsoulis, Konstantinos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19 |b The Potential of Autotaxin as a Therapeutic Target |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Ntatsoulis, Karampitsakos, Tsitoura, Stylianaki, Matralis, Tzouvelekis, Antoniou and Aidinis. | ||
| 520 | |a Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a Autotaxin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a lysophosphatidic acid | |
| 650 | 4 | |a pulmonary fibrosis | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Lysophospholipids |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Phosphoric Diester Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.1.4.- |2 NLM | |
| 650 | 7 | |a alkylglycerophosphoethanolamine phosphodiesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.4.39 |2 NLM | |
| 650 | 7 | |a lysophosphatidic acid |2 NLM | |
| 650 | 7 | |a PG6M3969SG |2 NLM | |
| 700 | 1 | |a Karampitsakos, Theodoros |e verfasserin |4 aut | |
| 700 | 1 | |a Tsitoura, Eliza |e verfasserin |4 aut | |
| 700 | 1 | |a Stylianaki, Elli-Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Matralis, Alexios N |e verfasserin |4 aut | |
| 700 | 1 | |a Tzouvelekis, Argyrios |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Aidinis, Vassilis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 12(2021) vom: 01., Seite 687397 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:01 |g pages:687397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2021.687397 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 01 |h 687397 | ||